More News! Desktop Genetics Looks to Raise £1.5M “For Growth”

Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

  • An innovation hub is coming to Karlsruher, thanks to a €30M investment from ZEISS.
  • Desktop Genetics is looking to raise another £1.5M “for growth.”
  • Omeicos is expanding in a variety of areas: it has extended its Series B, is trying to push its tech into ophthalmology, and moving to establish a subsidiary in Boston.
  • Lunaphore raked in 6M CHF for its cancer tissue diagnostics aimed at hospitals and laboratories.
  • The US government granted Addex $5.3M (€4.5M) to work on treatments for cocaine abuse.
  • Transgene counts with a new partner, Randox, to develop multifunctional virotherapies for solid tumors.
  • Cell & Gene Therapy Catapult has partnered with Forum for Innovative Regenerative Medicine in Japan to accelerate research and commercialization of regenerative therapies.
  • Novadiscovery, a startup that pitched at Refresh, signed on to collaborate with Enyo Pharma in the development of its lead candidate.
  • AMR has in-licensed an antibiotic candidate from Medivir in a deal of undisclosed value.
  • Promethera is partnering with Shibuya to establish a cell therapy and regenerative medicine manufacturing platform.

ADVERTISEMENT

  • Noxxon has proved the concept of its lead compound NOX-A12 in combination with checkpoint inhibitors in a preclinical study.
  • Vantia’s fedovapagon for nocturne met its endpoints in a Phase III trial.
  • TiGenix has announced Cx601 is effective at the 52-week mark for the treatment of Crohn’s disease and will present more detailed results at ACG 2017.

  • Milner Therapeutics Institute debuted a global 65 institution-strong alliance to collaborate on research in Cambridge.
  • Apogenix received Orphan Designation from the European Commission for its immuno-oncology candidate asunercept to treat Myelodysplastic Syndromes.
  • Sanofi & Regeneron beat back Amgen in a PCSK9 patent appeal.

Images via kunanon, warmer, nattanan726 / shutterstock.com

SaveSave

Let's Continue The Conversation

Feel free to send us comments about this article to [email protected] and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and its' freely accessible content.